Archive for February, 2011
Initial Report on Adolor (ADLR, $1.38)
Adolor as a Stock While I am currently neutral on Adolor, it is a stock that I am watching closely. To become more positive, I need to gain more confidence that their lead drug Entereg, which has had a slower than expected sales ramp up since its introduction in 3Q, 2008 can grow from a […]